发明名称 |
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma |
摘要 |
The present invention relates to diagnostic, prognostic and clinical methods of distinguishing high-risk IPMN from more benign IPMN as well as high-grade PanIN and PDAC from low-grade PanIN with moderate sensitivity and very high specificity using Das-1 and related antibodies. |
申请公布号 |
US9575073(B2) |
申请公布日期 |
2017.02.21 |
申请号 |
US201213648921 |
申请日期 |
2012.10.10 |
申请人 |
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY;MASSACHUSETTS GENERAL HOSPITAL |
发明人 |
Das Kiron M.;Das Koushik K.;Mino-Kenudson Mari |
分类号 |
G01N33/53;G01N33/574;G01N33/68 |
主分类号 |
G01N33/53 |
代理机构 |
Fox Rothschild LLP |
代理人 |
Fox Rothschild LLP |
主权项 |
1. A method for determining whether a subject has high-risk intraductal papillary mucinous neoplasm (IPMN) of the pancreas comprising:
contacting a pancreatic fluid sample selected from the group consisting of a pancreatic cyst fluid and pancreatic juice from a subject suspected of having high-risk IPMN with a Das-1 antibody or an antigen binding portion thereof, wherein said Das-1 antibody is produced by a hybridoma deposited under American Type Culture Collection (ATCC) accession number HB 9397; and detecting the presence or absence of immunoreactivity between the pancreatic fluid sample and the antibody or the antigen binding portion thereof, the presence of the immunoreactivity indicating a positive diagnosis of having high-risk IPMN. |
地址 |
New Brunswick NJ US |